Middle East And Turkey Hemophilia Treatment Market Analysis

Middle East and Turkey Hemophilia Treatment Market Insights

Hemophilia is treated with recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Most of the patients with hemophilia prefer factor replacement therapy as primary treatment, owing to its positive outcomes. Increasing approval and launches of recombinant coagulation factor in the Middle East region are expected to drive growth of the recombinant coagulation factor segment in Middle East and Turkey hemophilia treatment market. For instance, in October 2017, Swedish Orphan Biovitrum AB (publ) received approval for its Alprolix (eftrenonacog alfa, Coagulation Factor IX (Recombinant), for the treatment of hemophilia B, from Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia.

The Middle East and Turkey hemophilia treatment market is estimated to be valued at US$ 645.1 million in 2019, and is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027).

Figure 1. Middle East and Turkey Hemophilia Treatment Market Share (%), By Product Type, (2019 & 2027)

Source: Coherent Market Insights Analysis (2019)

Approval and launches of such novel products in the market are expected to boost the growth of Middle East and Turkey hemophilia treatment market over the forecast period

Increasing product approvals by the key players is expected to drive the market growth over the forecast period. For instance, in August 2018, Bayer AG, received the U.S. Food and Drug Administration approval for its new hemophilia A treatment product, Jivi with flexible dosing regimen. It is used for the treatment of bleeding in adults and adolescents (12 years of age and above), who were previously treated for hemophilia A. Moreover, in February 2018, Shire Plc , the local branch of the global biotech pharmaceutical Shire, received approval from the Ministry of Food and Drug Safety for Adynovate, a long-lasting factor VIII gene recombinant for hemophilia A treatment.

Furthermore, key players are focused on adopting growth strategies such as acquisitions that is expected to drive the Middle East and Turkey hemophilia treatment market growth over the forecast period. For instance, in April 2014, Baxter International Inc. acquired Chatham Therapeutics, LLC, a privately held clinical development-stage biotechnology company engaged in development of novel, gene therapy-mediated treatments for hemophilia. Baxter acquired Chatham's developmental gene therapy platform to facilitate development and commercialization of hemophilia treatment.

Middle East and Turkey Hemophilia Treatment Market- Restraints

High cost of treatment for hemophilia is a major factor, which is expected to hinder the market growth over the forecast period. Hemophilia is associated with high aggregate costs and imposes a high financial burden on individuals, and healthcare systems in emerging economies. Hemophilia is a chronic condition that requires lifelong treatment, with individual costs varying based on disease severity, complications, and treatment regimen. For instance, according to a cohort study conducted by National Center for Biotechnology Information (NCBI) in 2015, hemophilia treatment is expensive, particularly for patients with severe hemophilia. According to the study, severe hemophilia is associated with greater annual costs in both types of hemophilia. For instance, according to the study NCBI in 2015, the annual cost required for the treatment of hemophilia A is around US$ 84,766.9 and hemophilia B is around US$ 122,877. Patients with factor VIII inhibitors have costs 3.3 times higher than patients without factor VIII inhibitors. Thus, high cost of therapy is expected to hinder the market growth over the forecast period.

Middle East and Turkey Hemophilia Treatment Market- Regional Analysis

Country wise segmentation of the Middle East and Turkey Hemophilia Treatment Market include Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East.

Among countries, Turkey is expected to witness a significant growth in the Middle East and Turkey hemophilia treatment market over the forecast period, owing to availability of the hemophilia drugs and increasing patient population are expected to propel the market growth in Turkey over the forecast period. For instance, Baxalta Incorporated produced ADYNOVATE, an antihemophilic recombinant factor indicated for the patients above 12 years suffering from Hemophilia A. It is available in Turkey and other 66 countries, globally.

Furthermore, rising support of market players and government organizations in providing access to hemophilia drugs for people is expected to fuel the market growth in Egypt over the forecast period. For instance, In November 2017, Octapharma AG, in collaboration with Project SHARE, donated 30.5 million units of human cell-line derived recombinant factor VIII product, Nuwiq, for the treatment of patients with hemophilia A in emerging economies such as Bangladesh, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Myanmar, Nepal, and others.

Figure 2: Middle East and Turkey Hemophilia Treatment Market Share (%), By Country, (2019 & 2027)

Source: Coherent Market Insights Analysis (2019)

Middle East and Turkey Hemophilia Treatment Market- Competitive Landscape

Key players operating in the Middle East and Turkey hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and  Spark Therapeutics, Inc.